Published 5 days ago • loading... • Updated 5 days ago

Dr Evens on Personalizing Therapy for Patients with Hodgkin Lymphoma

Summary by targetedonc.com

Andrew Evens, DO, MBA, MSc, discusses the HOLISTIC consortium, which aims to gather and harmonize global Hodgkin lymphoma data from clinical trials and registries.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

Patient Worthy

Milestone Reached: First Patient Dosed in Phase 3 Trial of Innovative Blood Cancer Therapy – Patient Worthy

A significant milestone has been achieved in the fight against blood cancers, as the first patient has been dosed in a pivotal Phase 3 clinical trial evaluating a promising new therapy. As reported by Yahoo! Finance, this advancement signals hope for patients with limited treatment options and underscores the momentum of innovation in hematological cancer […]

5 days ago

Read Full Article

targetedonc.com

Dr Evens on Personalizing Therapy for Patients with Hodgkin Lymphoma

Andrew Evens, DO, MBA, MSc, discusses the HOLISTIC consortium, which aims to gather and harmonize global Hodgkin lymphoma data from clinical trials and registries.

5 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right